Please assess the completion status of the following clinical trial:

Trial Title: Pre-medication With Alfentanil vs Placebo During ECT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> /=18 years~* Males or females~* Anticipating electroconvulsive therapy to treat refractory depressive disorder~Exclusion Criteria:~* Under the age of 18~* Allergy to alfentanil~* Allergy to other standard anesthetic medications utilized in the course of ECT (glycopyrrolate, methohexital, and succinylcholine)~* History of malignant hyperthermia~* History of severe airway obstruction, bronchospasm or laryngospasm~* History of recent myocardial infarction, ventricular arrhythmia~* Adverse reaction to ECT requiring premedication with lidocaine or atropine~* Non-English speaking~* Patients unable to consent for themselves~* Current pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alfentanil (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).